Edition:
United States

AstraZeneca PLC (AZN.N)

AZN.N on New York Stock Exchange

34.08USD
23 May 2017
Change (% chg)

$0.13 (+0.38%)
Prev Close
$33.95
Open
$33.90
Day's High
$34.14
Day's Low
$33.88
Volume
686,450
Avg. Vol
935,727
52-wk High
$35.03
52-wk Low
$25.56

Latest Key Developments (Source: Significant Developments)

Genomic Vision to enter into technological collaboration with AstraZeneca in oncology
Tuesday, 23 May 2017 02:00am EDT 

May 23 (Reuters) - GENOMIC VISION SA ::GENOMIC VISION TO ENTER INTO TECHNOLOGICAL COLLABORATION WITH ASTRAZENECA IN ONCOLOGY.HAVE ENTERED INTO A TECHNOLOGICAL COLLABORATION WITH ASTRAZENECA IN FIELD OF TARGETING DNA DAMAGE RESPONSE (DDR) FOR NOVEL ANTI-CANCER TREATMENTS STRATEGY.  Full Article

Recordati acquires from AstraZeneca European rights to Metoprolol based products
Monday, 22 May 2017 02:13am EDT 

May 22 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA ::ACQUIRES FROM ASTRAZENECA <<>> EUROPEAN RIGHTS TO PRODUCTS BASED ON METOPROLOL.THE CONSIDERATION FOR THE ACQUISITION OF THE ASSETS IS OF $ 300 MILLION (APPROX. € 270 MILLION) AND WILL BE FUNDED BY EXISTING LIQUIDITY AND AVAILABLE CREDIT LINES.ROYALTIES FOR THE USE OF THE EXISTING PRODUCT BRANDS WILL BE DUE TO ASTRAZENECA FOR AN AGREED PERIOD.METOPROLOL SUCCINATE IS A BETA‐BLOCKER FOR THE CONTROL OF HYPERTENSION, ANGINA AND HEART FAILURE.EXISTING SALES OF THE METOPROLOL BRANDS WILL PROVIDE THE BASE TO ENTER NEW MARKETS AND COMPLETE EUROPEAN GEOGRAPHICAL FOOTPRINT.  Full Article

AstraZeneca says Leo Pharma has received positive opinion from CHMP of EMA recommending approval of Brodalumab
Friday, 19 May 2017 12:32pm EDT 

May 19 (Reuters) - AstraZeneca Plc ::Brodalumab receives positive chmp opinion for treatment of adult patients with moderate-to-severe plaque psoriasis.co's partner Leo Pharma has received positive opinion from CHMP of EMA recommending approval of Brodalumab.  Full Article

Inovio pharmaceuticals says AstraZeneca's MedImmune will start new clinical trial
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Inovio Pharmaceuticals Inc :Inovio provides update on MedImmune launch of combination trial for hpv-associated head & neck cancer.Inovio Pharmaceuticals-AstrazZneca's medimmune will start a new clinical trial investigating combination of medi0457.Inovio Pharmaceuticals-new clinical trial will investigate combination of medi0457 and durvalumab, an investigational pd-l1 checkpoint inhibitor.  Full Article

Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma
Tuesday, 2 May 2017 03:36pm EDT 

May 2 (Reuters) - Roche Holding Ag : :Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma.Continues to pursue regulatory approval for Ventana PD-L1 (SP263) assay in other cancer indications in US and in other geographies.  Full Article

AstraZeneca's durvalumab average monthly cost around $15,000
Monday, 1 May 2017 02:56pm EDT 

May 1 (Reuters) - AstraZeneca :Says average wholesale acquisition cost of durvalumab around $15,000/month, following FDA approval of drug for bladder cancer.  Full Article

FDA grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma
Monday, 1 May 2017 01:10pm EDT 

May 1 (Reuters) - U.S. FDA :Grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma.Approved Ventana PD-l1 assay as complementary diagnostic for assessment of PD-l1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue.  Full Article

GSK still in talks with AstraZeneca about start date for Luke Miels
Wednesday, 26 Apr 2017 10:26am EDT 

April 26 (Reuters) - GlaxoSmithKline Plc CEO Emma Walmsley told analysts::"no comment" on whether would launch authorised advair generic in u.s..still in discussion with AstraZeneca about date for Luke Miels to join GSK.  Full Article

AstraZeneca's lung cancer drug receives full EU approval
Tuesday, 25 Apr 2017 08:30am EDT 

April 25 (Reuters) - AstraZeneca Plc ::Tagrisso receives full approval in the EU.European Commission has granted full marketing authorisation for Tagrisso (osimertinib).Grant for treatment of adults with locally-advanced or metastatic epidermal growth factor receptor T790m mutation-positive non-small cell lung cancer.In March 2017, US Food and Drug Administration granted Tagrisso a conversion from accelerated to full approval.Warnings and precautions include interstitial lung disease (ILD), keratitis, left ventricular ejection fraction (LVEF) and QTC interval prolongation.  Full Article

Aralez Pharma says co and U.S. Government entered into modification of contract
Tuesday, 11 Apr 2017 04:30pm EDT 

Aralez Pharmaceuticals Inc : Aralez Pharma - on April 6, aralez us and u.s. government entered into modification of contract under which government exercised first renewal option under deal .Aralez Pharmaceuticals Inc - U.S. Government extended term of agreement by one year to April 28, 2018 with modified pricing for duration thereof.  Full Article

More From Around the Web

AstraZeneca asthma shot hits goal but diabetes drug lags rival

LONDON AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.